Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Dionysis Papadatos-Pastos; Wei Yuan; Abhijit Pal; Mateus Crespo; Ana Ferreira; Bora Gürel; Toby Prout; Malaka Ameratunga; Maxime Chénard-Poirier; Andra Curcean; Cláudia Bertan; Chloe Baker; Susana Miranda; Nahal Masrour; Wentin Chen; Rita Pereira; Ines Figueiredo; Ricardo Morilla; Ben Jenkins; Anna Zachariou; Ruth Riisnaes; Mona Parmar; Alison Turner; Suzanne Carreira; Christina Yap; Robert Brown; Nina Tunariu; Udai Banerji; Juanita Lopez; Johann S. de Bono; Anna Minchom

doi:10.1136/jitc-2022-004495

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Guadecitabine in combination with pembrolizumab is tolerable with biological and anticancer activity. Reversal of previous resistance to immune checkpoint inhibitors is demonstrated.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Papadatos-Pastos et al. (2022) studied this question.

synapsesocial.com/papers/69d9d6b184371aa676a3c01d https://doi.org/10.1136/jitc-2022-004495

View Full Paper

Ask AI

Bookmark

Share

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Ask about this paper

Abstract

Discussion

Cite This Study

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading